Anisakis, Parasite, IgE, Serum
Use
Establishing a diagnosis of an allergy to the Anisakis parasite and defining the allergen responsible for eliciting signs and symptoms. Identifies allergens responsible for allergic response and/or anaphylactic episode, confirms sensitization prior to beginning immunotherapy, and investigates the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens. Testing for IgE antibodies is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists or in patients where the management does not depend on identification of allergen specificity.
Special Instructions
Not provided.
Limitations
Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum, and test results must be interpreted in the clinical context. False-positive results for IgE antibodies may occur in patients with markedly elevated IgE levels (>2500 kU/L) due to nonspecific binding to allergen solid phases.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Fluorescence Enzyme Immunoassay (FEIA))
Biomarkers
IgE
Protein
LOINC Codes
- 10919-9 - Anisakis IgE Qn
- 10919-9 - Anisakis IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL for every 5 allergens requested
Minimum Volume
For 1 allergen: 0.3 mL; For more than 1 allergen: (0.05 mL x number of allergens) + 0.25 mL deadspace
Container
Plastic vial (Preferred: Serum gel; Acceptable: Red top)
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |